146 related articles for article (PubMed ID: 9673299)
1. A vaccine consisting of recombinant Borrelia burgdorferi outer-surface protein A to prevent Lyme disease. Recombinant Outer-Surface Protein A Lyme Disease Vaccine Study Consortium.
Sigal LH; Zahradnik JM; Lavin P; Patella SJ; Bryant G; Haselby R; Hilton E; Kunkel M; Adler-Klein D; Doherty T; Evans J; Molloy PJ; Seidner AL; Sabetta JR; Simon HJ; Klempner MS; Mays J; Marks D; Malawista SE
N Engl J Med; 1998 Jul; 339(4):216-22. PubMed ID: 9673299
[TBL] [Abstract][Full Text] [Related]
2. An effective second-generation outer surface protein A-derived Lyme vaccine that eliminates a potentially autoreactive T cell epitope.
Willett TA; Meyer AL; Brown EL; Huber BT
Proc Natl Acad Sci U S A; 2004 Feb; 101(5):1303-8. PubMed ID: 14742868
[TBL] [Abstract][Full Text] [Related]
3. The immunoglobulin (IgG) antibody response to OspA and OspB correlates with severe and prolonged Lyme arthritis and the IgG response to P35 correlates with mild and brief arthritis.
Akin E; McHugh GL; Flavell RA; Fikrig E; Steere AC
Infect Immun; 1999 Jan; 67(1):173-81. PubMed ID: 9864212
[TBL] [Abstract][Full Text] [Related]
4. Structure of a transmission blocking antibody in complex with Outer surface protein A from the Lyme disease spirochete, Borreliella burgdorferi.
Rudolph MJ; Davis SA; Haque HME; Ejemel M; Cavacini LA; Vance DJ; Willsey GG; Piazza CL; Weis DD; Wang Y; Mantis NJ
Proteins; 2023 Nov; 91(11):1463-1470. PubMed ID: 37455569
[TBL] [Abstract][Full Text] [Related]
5. Cellular and molecular aspects of Lyme arthritis.
Gross DM; Huber BT
Cell Mol Life Sci; 2000 Oct; 57(11):1562-9. PubMed ID: 11092451
[TBL] [Abstract][Full Text] [Related]
6. Development of an mRNA-lipid nanoparticle vaccine against Lyme disease.
Pine M; Arora G; Hart TM; Bettini E; Gaudette BT; Muramatsu H; Tombácz I; Kambayashi T; Tam YK; Brisson D; Allman D; Locci M; Weissman D; Fikrig E; Pardi N
Mol Ther; 2023 Sep; 31(9):2702-2714. PubMed ID: 37533256
[TBL] [Abstract][Full Text] [Related]
7. The major epidemiologic, microbiologic, immunologic, and clinical aspects of Lyme disease that form the basis for a newly developed vaccine that may become available soon for human use.
Pavia CS; Saggio G; Plummer MM
Front Immunol; 2023; 14():1326623. PubMed ID: 38420513
[TBL] [Abstract][Full Text] [Related]
8. In vitro assessment of antiborrelial activity of OspA vaccine sera.
Fawcett PT; Rose CD; Gibney KM
Clin Diagn Lab Immunol; 2002 Jul; 9(4):919-20. PubMed ID: 12093696
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and antigenicity of BBGL-2 glycolipids of Borrelia burgdorferi, the causative agent of Lyme disease.
Pozsgay V; Kubler-Kielb J; Coxon B; Marques A; Robbins JB; Schneerson R
Carbohydr Res; 2011 Sep; 346(12):1551-63. PubMed ID: 21601180
[TBL] [Abstract][Full Text] [Related]
10. Design of a broadly reactive Lyme disease vaccine.
Kamp HD; Swanson KA; Wei RR; Dhal PK; Dharanipragada R; Kern A; Sharma B; Sima R; Hajdusek O; Hu LT; Wei CJ; Nabel GJ
NPJ Vaccines; 2020; 5(1):33. PubMed ID: 32377398
[TBL] [Abstract][Full Text] [Related]
11. Antibody-mediated immunological memory correlates with long-term Lyme veterinary vaccine protection in mice.
Gutierrez MP; Huckaby AB; Yang E; Weaver KL; Hall JM; Hudson M; Dublin SR; Sen-Kilic E; Rocuskie-Marker CM; Miller SJ; Pritchett CL; Mummadisetti MP; Zhang Y; Driscoll T; Barbier M
Vaccine; 2024 Jun; ():. PubMed ID: 38937181
[TBL] [Abstract][Full Text] [Related]
12. Biophysical and biochemical characterization of a recombinant Lyme disease vaccine antigen, CspZ-YA.
Chen YL; Lee J; Liu Z; Strych U; Bottazzi ME; Lin YP; Chen WH
Int J Biol Macromol; 2024 Feb; 259(Pt 2):129295. PubMed ID: 38211914
[TBL] [Abstract][Full Text] [Related]
13. Lyme disease vaccine.
Halperin SA
Can J Infect Dis; 2000 May; 11(3):132-4. PubMed ID: 18159278
[No Abstract] [Full Text] [Related]
14. Single-domain antibodies reveal unique borrelicidal epitopes on the Lyme disease vaccine antigen, outer surface protein A (OspA).
Vance DJ; Basir S; Piazza CL; Willsey GG; Haque HME; Tremblay JM; Rudolph MJ; Muriuki B; Cavacini L; Weis DD; Shoemaker CB; Mantis NJ
Infect Immun; 2024 Apr; 92(4):e0008424. PubMed ID: 38470113
[TBL] [Abstract][Full Text] [Related]
15. Intranasal vaccine for Lyme disease provides protection against tick transmitted Borrelia burgdorferi beyond one year.
Gingerich MC; Nair N; Azevedo JF; Samanta K; Kundu S; He B; Gomes-Solecki M
NPJ Vaccines; 2024 Feb; 9(1):33. PubMed ID: 38360853
[TBL] [Abstract][Full Text] [Related]
16. The Development of a Rabies Virus-Vectored Vaccine against
Rios S; Bhattachan B; Vavilikolanu K; Kitsou C; Pal U; Schnell MJ
Vaccines (Basel); 2024 Jan; 12(1):. PubMed ID: 38250891
[TBL] [Abstract][Full Text] [Related]
17. Prospective incidence epidemiology study protocol: conducting active surveillance to assess the burden of Lyme disease (BOLD) in primary care practices in endemic areas of six European countries.
Begier E; Pilz A; Loew-Baselli A; Harper LR; Stark JH; Bowdery M; Halsby K; Dzingina M; Bézay N; Allen KE; Parslow B; Gessner BD
BMJ Open; 2023 Dec; 13(12):e070903. PubMed ID: 38072499
[TBL] [Abstract][Full Text] [Related]
18. A Retrospective Study with a Commercial Vaccine against Lyme Borreliosis in Dogs Using Two Different Vaccination Schedules: Characterization of the Humoral Immune Response.
Wilczek CK; Wenderlein J; Hiereth S; Straubinger RK
Vaccines (Basel); 2022 Dec; 11(1):. PubMed ID: 36679888
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
